MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.6 CNY | +1.33% |
|
-3.97% | +2.78% |
| 05-07 | Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821 | CI |
| 04-29 | Mabwell Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Evolution of the average Target Price on Mabwell (Shanghai) Bioscience Co., Ltd.
Price target over the last 5 years
History of analyst recommendation changes
d114ee8bacdcec0e9bacf8f1778.-pkxLR7b0JIlFkifgfle-XqK1ELu0C9h1fu86wss2wQ.zq1HdEuovt9gVBLH6I0qvwLG5i-ghE0XspORp2RzrlKP-lhBdILp101mIw~3f00c7afa114815709575abee7a2f810
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
33.6
CNY
Average target price
39.92
CNY
Spread / Average Target
+18.79%
High Price Target
48
CNY
Spread / Highest target
+42.86%
Low Price Target
31.83
CNY
Spread / Lowest Target
-5.27%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
- Stock Market
- Equities
- 688062 Stock
- Consensus Mabwell (Shanghai) Bioscience Co., Ltd.
